RVPH earnings analysis
What we found in RVPH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q text does not include quantitative income-statement, balance-sheet or cash-flow data, but it discloses pervasive material weaknesses in internal controls as of June 30, 2026. Reviva remains dependent on the successful development and approval of brilaroxazine, with no approved commercial products and no NDA submitted. The May 2026 Nasdaq delisting and transition to OTCQB create additional liquidity and equity-financing risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Remediation efforts initiated
- Management commenced remediation of the disclosed control deficiencies by hiring an additional internal accounting resource and engaging a third-party consulting firm for IT general controls. The filing also describes continued personnel realignment to strengthen management review and documentation.
- Financial statements deemed fairly presented
- The company states that its unaudited condensed consolidated financial statements fairly present its financial position, results of operations and cash flows in all material respects and conform to U.S. GAAP.
- No unregistered equity sales
- The company reported no unregistered sales of equity securities during the quarter ended June 30, 2026.
- No insider trading arrangements
- No officers or directors adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the quarter ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Pervasive material weaknesses
- As of June 30, 2026, management concluded that disclosure controls and procedures were ineffective. The company identified pervasive material weaknesses in its control environment, IT general controls and process-level controls affecting substantially all account balances and disclosures.
- Dependence on unapproved brilaroxazine
- The company has no products approved for commercial sale and states that its business depends heavily on brilaroxazine, its only advanced product candidate. The company has not submitted an NDA and does not expect to be in a position to do so for the foreseeable future, pending additional development activities including the planned bioequivalence study and RECOVER-2 trial.
- Nasdaq delisting and financing risk
- The company received a Nasdaq delisting determination on May 12, 2026, was suspended from Nasdaq trading on May 14, 2026, and is now quoted on the OTCQB Venture Market. Management states the delisting may reduce liquidity and market price, limit investors and impair the company’s ability to raise equity financing.
- OTCQB liquidity and compliance risk
- The company states that OTC Markets trading is often thin, sporadic and volatile, with wide price fluctuations, and warns that failure to comply with OTCQB continuing listing requirements could result in delisting. The filing also notes that the common stock may fall within the definition of a penny stock.
- Potential additional clinical trials
- The company identifies potential regulatory and clinical execution risks, including the possibility that the FDA may require additional Phase 3 trials. Such a requirement would increase costs and prolong development of brilaroxazine.
What they said about what is next.
No quantitative financial guidance is provided in the supplied 10-Q text. The filing discusses operational development timing but does not provide revenue or EPS targets.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Reviva Pharmaceuticals Holdings, Inc. reported a notable improvement in its net loss for Q1 2026, narrowing it to approximately $3.2 million or $0.46 per share, compared to a loss of $6.4 million or $2.61 per share in…
- 10-K · March 30, 2026
- Reviva Pharmaceuticals (RVPH) is a late‑stage biopharma focused on brilaroxazine (RP5063) with completed toxicology and a positive Phase 2 acute schizophrenia study (N = 234) where the 15 mg (p = 0.0212) and 50 mg (p =…
- 10-Q · November 13, 2025
- Reviva reported a smaller net loss of $4,010,773 for 2025Q3 versus $8,365,798 in 2024Q3, driven by a decline in operating expenses (total operating expenses fell to $4,029,841 from $8,462,534). Cash and cash equivalents…
- 10-Q · August 14, 2025
- Reviva reported a net loss of $6,053,610, or $(0.12) per share, for the quarter ended June 30, 2025, an improvement versus the prior-year quarter net loss of $7,859,919, or $(0.26) per share. Total operating expenses…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RVPH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever